Recent Updates
Recently added Catalysts

Upcoming Catalyst

Drug Pipeline Intelligence

Clinical Trial Results

Inside Trades

Options Data

News Section

Hedge Funds

Ownership Trends

Competitive Position

Zenas BioPharma, Inc.

35 indications, side-by-side phase, drug & LoA

$19.8

+2.04 (+11.49%)

B 62Pipeline Score Fair Value Biotech · Commercial
Market Cap
1.20 B
EPS
-9.10
P/E Ratio
-
Value Trade
7.25 M
SEC Financials
Q1 2026

  • Dilution Risk

    5%

  • R&D Expenses

    60.44 M

  • Operating CF

    -75.20 M

  • Total Assets

    747.68 M

  • Total Liabilities

    411.85 M

  • Equity

    335.83 M

  • D/E Ratio

    12,345

2.82 %
Week
-8.22 %
1 Month
-28.9 %
3 Month
-45.55 %
6 Month
3.38 %
5 Year
3.38 %
All Time
Cash Data
Healthy

  • Cash Position

    717.20 M

  • Monthly Burn

    25.07 M

  • Runway

    27.7 mo

  • Burn Trend

    Accelerating

  • SEC Filing

    May 13, 2026
Overview
Volume
1.32 M
52 Week Range
8.91 - 44.60
% held by Insiders
49.61 %
% held by Institutions
63.55 %
Enterprise Value
832.16 M
Total Shares
57.34 M
Short %
48.03 %
Float Shares
22.65 M
Company Description
HQ: 852 WINTER STREET, SUITE 250, ...
Employees:167
https://www.zenasbio.com

locked

Upcoming Catalyst
Catalyst Drug/Treatment Stage Probability of Approval Description Drug Type Therapeutic Area Source
Top-line Data example
Obexelimab Systemic Lupus Erythematosus (SLE)
Phase 2
—
Biologics
Immunology
Obexelimab Systemic Lupus Erythematosus (SLE)
Phase 2
—
Biologics
Immunology
Obexelimab Systemic Lupus Erythematosus (SLE)
Phase 2
—
Biologics
Immunology
Unlock Upcoming Catalyst data
Drug Pipeline Intelligence
B62
Pipeline Score
$2.2B
Pipeline Value
Fair Value
Valuation Signal
5
Drugs Scored
1.9x
rNPV / MCap
Top 90%
Micro Cap
(rank 91 of 905)
Percentile Rank
Zenas BioPharma, Inc. holds a solid B-grade pipeline (62/100), with $5.5B risk-adjusted pipeline value, led by Orelabrutinib in Secondary Progressive Multiple Sclerosis (Phase 3), across $70B in total addressable markets.
Showing 1 of 1 assets
DrugIndicationPhaseNCT IDPTRSrNPVStatusEnrollmentVelocityDesignCompletionML SignalLast Change
Orelabrutinib
Small molecule		Multiple Sclerosis (MS) Primary ProgressivePhase 3NCT0706746358% $4.2B RECRUITING 705 VERY_FAST B (62) Jul 1, 2030LOW_RISKLOW
May 29, 2026
Unlock Drug Pipeline Intelligence
Clinical Trial Results
Drug Name Indications Phase Date Trial Results Summary Title Source
obexelimab
IgG4-Related Disease,Relapsing Multiple Sclerosis,Systemic Lupus Erythematosus
Phase 3
2025-09-03
obexelimab
IgG4-Related Disease,Relapsing Multiple Sclerosis,Systemic Lupus Erythematosus
Phase 3
2025-09-03
obexelimab
IgG4-Related Disease,Relapsing Multiple Sclerosis,Systemic Lupus Erythematosus
Phase 3
2025-09-03
Unlock Clinical Trial Results data
Inside Trades
TREND
CORPORATE INSIDERS BOUGHT SHARES WORTH 1.8M IN THE LAST 3 MONTHS
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Unlock Inside Trades data
Show Data
Hedge Funds
TREND
HEDGE FUNDS INCREASED HOLDINGS BY 200.0K SHARES IN THE LAST QUARTER
Shares Held
2040.00B1530.00B1020.00B510.00B0
Q3
2024
Q4
2024
Q1
2025
Q2
2025
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Fund Count
60%
Share Volume
25%
Conviction
15%
Hedge Funds invested in ZBIO
HedgeFund Name
( 3 )
% of Portfolio Current MV
-
Shares Owned
-
Activity
Avg Price $0

Example Capital Management

2.5 %
15.00 M
250.00 K

Example Capital Management

2.5 %
15.00 M
250.00 K

Example Capital Management

2.5 %
15.00 M
250.00 K
Unlock Hedge Funds table data
Biotech Analyst Ratings
Symbol
Firm
Rating
Action
Price Target
Upside
date
ZBIO
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
ZBIO
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
ZBIO
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
Unlock Biotech Analyst Ratings data
ZBIO Stock Forecast & Analyst Consensus
BUY
Analyst Ratings
Buy65.0%
Hold25.0%
Sell10.0%
Price Target Trend
Average$24.00
Low$18.00
High$32.00
Unlock Price Target Trend
ZBIO Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
ExpirationVolumeOpen InterestImplied Volatility CallsImplied Volatility Puts
CallsPutsPut-Call RatioCallsPutsPut-Call RatioIVOiWaIvVWaIvIVOiWaIvVWaIv
2026-07-170 0.00 0 0 - - - - - -
2026-07-170 0.00 0 0 - - - - - -
2026-07-170 0.00 0 0 - - - - - -
Unlock Option Chain Statistics data
Option Chain
CallsStrikePuts
Last PriceVolumeOpen InterestLast PriceVolumeOpen Interest
No data available
Unlock Option Chain data
Unlock Options Chart data
Open interest
0 600K 1.2M 1.8M Avg OI 1.00 M Open Interest
0 1 2 3 1.1 Put-Call Ratio
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
0 450K 900K 1.4M Avg OV 750.00 K Option Volume
0 1 2 3 0.95 Put-Call Ratio
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Latest Zenas BioPharma, Inc. (ZBIO) News & Alerts
-
Sunday, June 14, 2026
(%)
+ More

Demo Biotech Announces Positive Phase 3 Results

Competitive Position
How ZBIO ranks across every disease it competes in
Indication Rank Phase Best DrugTop 3 Competitors Market $B LoA Position
Rare Immunological Disorders #2 of 10 PHASE 3 Obexelimab
AMGN PHVS NVS
—0.98 CONTENDER
Autoimmune Hemolytic Anemia #2 of 8 PHASE 3 Obexelimab
NVS RIGL JNJ
$0.77B 0.99 CONTENDER
Multiple Sclerosis #6 of 20 PHASE 3 Orelabrutinib
SNY BMY NVS
$31.92B 0.99 CONTENDER
Systemic Lupus Erythematosus #10 of 32 PHASE 2 Obexelimab
BIIB BMY VTRS
$2.78B 0.98 FOLLOWER
Rheumatoid Arthritis #16 of 28 PHASE 1 ZB002
ABBV LLY BMY
$4.2B 0.99 FOLLOWER